The potential role of kynurenines in Alzheimer's disease: Pathomechanism and therapeutic possibilities by influencing the glutamate receptors

Zsófia Majláth, J. Toldi, L. Vécsei

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The pathomechanism of neurodegenerative disorders still poses a challenge to neuroscientists, and continuous research is under way with the aim of attaining an understanding of the exact background of these devastating diseases. The pathomechanism of Alzheimer's disease (AD) is associated with characteristic neuropathological features such as extracellular amyloid-β and intracellular tau deposition. Glutamate excitotoxicity and neuroinflammation are also factors that are known to contribute to the neurodegenerative process, but a cerebrovascular dysfunction has recently also been implicated in AD. Current therapeutic tools offer moderate symptomatic treatment, but fail to reduce disease progression. The kynurenine pathway (KP) has been implicated in the development of neurodegenerative processes, and alterations in the KP have been demonstrated in both acute and chronic neurological disorders. Kynurenines have been suggested to be involved in the regulation of neurotransmission and in immunological processes. Targeting the KP, therefore, offers a valuable strategic option for the attenuation of glutamatergic excitotoxicity, and for neuroprotection.

Original languageEnglish
Pages (from-to)881-889
Number of pages9
JournalJournal of Neural Transmission
Volume121
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Kynurenine
Glutamate Receptors
Alzheimer Disease
Therapeutics
Nervous System Diseases
Amyloid
Synaptic Transmission
Neurodegenerative Diseases
Disease Progression
Glutamic Acid
Research

Keywords

  • Alzheimer's disease
  • Dementia
  • Excitotoxicity
  • Glutamate
  • Kynurenine pathway
  • Neurodegeneration

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

@article{b82d91d7056845a4926d8dc9b6415253,
title = "The potential role of kynurenines in Alzheimer's disease: Pathomechanism and therapeutic possibilities by influencing the glutamate receptors",
abstract = "The pathomechanism of neurodegenerative disorders still poses a challenge to neuroscientists, and continuous research is under way with the aim of attaining an understanding of the exact background of these devastating diseases. The pathomechanism of Alzheimer's disease (AD) is associated with characteristic neuropathological features such as extracellular amyloid-β and intracellular tau deposition. Glutamate excitotoxicity and neuroinflammation are also factors that are known to contribute to the neurodegenerative process, but a cerebrovascular dysfunction has recently also been implicated in AD. Current therapeutic tools offer moderate symptomatic treatment, but fail to reduce disease progression. The kynurenine pathway (KP) has been implicated in the development of neurodegenerative processes, and alterations in the KP have been demonstrated in both acute and chronic neurological disorders. Kynurenines have been suggested to be involved in the regulation of neurotransmission and in immunological processes. Targeting the KP, therefore, offers a valuable strategic option for the attenuation of glutamatergic excitotoxicity, and for neuroprotection.",
keywords = "Alzheimer's disease, Dementia, Excitotoxicity, Glutamate, Kynurenine pathway, Neurodegeneration",
author = "Zs{\'o}fia Majl{\'a}th and J. Toldi and L. V{\'e}csei",
year = "2014",
doi = "10.1007/s00702-013-1135-5",
language = "English",
volume = "121",
pages = "881--889",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - The potential role of kynurenines in Alzheimer's disease

T2 - Pathomechanism and therapeutic possibilities by influencing the glutamate receptors

AU - Majláth, Zsófia

AU - Toldi, J.

AU - Vécsei, L.

PY - 2014

Y1 - 2014

N2 - The pathomechanism of neurodegenerative disorders still poses a challenge to neuroscientists, and continuous research is under way with the aim of attaining an understanding of the exact background of these devastating diseases. The pathomechanism of Alzheimer's disease (AD) is associated with characteristic neuropathological features such as extracellular amyloid-β and intracellular tau deposition. Glutamate excitotoxicity and neuroinflammation are also factors that are known to contribute to the neurodegenerative process, but a cerebrovascular dysfunction has recently also been implicated in AD. Current therapeutic tools offer moderate symptomatic treatment, but fail to reduce disease progression. The kynurenine pathway (KP) has been implicated in the development of neurodegenerative processes, and alterations in the KP have been demonstrated in both acute and chronic neurological disorders. Kynurenines have been suggested to be involved in the regulation of neurotransmission and in immunological processes. Targeting the KP, therefore, offers a valuable strategic option for the attenuation of glutamatergic excitotoxicity, and for neuroprotection.

AB - The pathomechanism of neurodegenerative disorders still poses a challenge to neuroscientists, and continuous research is under way with the aim of attaining an understanding of the exact background of these devastating diseases. The pathomechanism of Alzheimer's disease (AD) is associated with characteristic neuropathological features such as extracellular amyloid-β and intracellular tau deposition. Glutamate excitotoxicity and neuroinflammation are also factors that are known to contribute to the neurodegenerative process, but a cerebrovascular dysfunction has recently also been implicated in AD. Current therapeutic tools offer moderate symptomatic treatment, but fail to reduce disease progression. The kynurenine pathway (KP) has been implicated in the development of neurodegenerative processes, and alterations in the KP have been demonstrated in both acute and chronic neurological disorders. Kynurenines have been suggested to be involved in the regulation of neurotransmission and in immunological processes. Targeting the KP, therefore, offers a valuable strategic option for the attenuation of glutamatergic excitotoxicity, and for neuroprotection.

KW - Alzheimer's disease

KW - Dementia

KW - Excitotoxicity

KW - Glutamate

KW - Kynurenine pathway

KW - Neurodegeneration

UR - http://www.scopus.com/inward/record.url?scp=84924381876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924381876&partnerID=8YFLogxK

U2 - 10.1007/s00702-013-1135-5

DO - 10.1007/s00702-013-1135-5

M3 - Article

C2 - 24346138

AN - SCOPUS:84924381876

VL - 121

SP - 881

EP - 889

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 8

ER -